Projected Income Statement: AstraZeneca PLC

Forecast Balance Sheet: AstraZeneca PLC

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 11,867 24,383 22,923 22,510 24,570 20,263 12,878 3,070
Change - 105.47% -5.99% -1.8% 9.15% -17.53% -36.45% -76.16%
Announcement Date 11/02/21 10/02/22 09/02/23 08/02/24 06/02/25 - - -
1USD in Million
Estimates

Cash Flow Forecast: AstraZeneca PLC

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026 2027
CAPEX 1 961 1,091 1,091 1,361 1,924 2,472 2,462 2,423
Change - 13.53% 0% 24.75% 41.37% 28.46% -0.39% -1.58%
Free Cash Flow (FCF) 1 3,838 4,872 8,717 8,984 9,937 7,603 12,703 14,335
Change - 26.94% 78.92% 3.06% 10.61% -23.48% 67.07% 12.85%
Announcement Date 11/02/21 10/02/22 09/02/23 08/02/24 06/02/25 - - -
1USD in Million
Estimates

Forecast Financial Ratios: AstraZeneca PLC

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026 2027

Profitability

        
EBITDA Margin (%) 31.22% 20.27% 20.83% 29.64% 30.87% 33.97% 36.86% 38.31%
EBIT Margin (%) 27.58% 26.53% 30.1% 31.73% 31.31% 32.06% 33.92% 35.44%
EBT Margin (%) 14.71% -0.71% 5.64% 15.06% 16.07% 21.96% 25% 26.65%
Net margin (%) 12.01% 0.3% 7.41% 13.01% 13.01% 17.15% 19.53% 20.74%
FCF margin (%) 14.42% 13.02% 19.65% 19.61% 18.38% 13.15% 20.76% 22.2%
FCF / Net Income (%) 120.09% 4,350% 265.12% 150.71% 141.25% 76.65% 106.33% 107.04%

Profitability

        
ROA 4.99% 8.77% 3.26% 11.48% 12.51% 10.81% 11.85% 12.68%
ROE 36.72% 27.51% 27.23% 29.77% 32.11% 31.78% 32% 31.59%

Financial Health

        
Leverage (Debt/EBITDA) 1.43x 3.21x 2.48x 1.66x 1.47x 1.03x 0.57x 0.12x
Debt / Free cash flow 3.09x 5x 2.63x 2.51x 2.47x 2.67x 1.01x 0.21x

Capital Intensity

        
CAPEX / Current Assets (%) 3.61% 2.92% 2.46% 2.97% 3.56% 4.27% 4.02% 3.75%
CAPEX / EBITDA (%) 11.56% 14.38% 11.81% 10.02% 11.53% 12.58% 10.92% 9.79%
CAPEX / FCF (%) 25.04% 22.39% 12.52% 15.15% 19.36% 32.51% 19.38% 16.9%

Items per share

        
Cash flow per share 1 3.655 4.179 6.287 6.623 7.589 10.43 11.52 13.16
Change - 14.33% 50.46% 5.34% 14.58% 37.48% 10.39% 14.27%
Dividend per Share 1 2.8 2.87 2.9 2.9 3.1 3.213 3.376 3.535
Change - 2.5% 1.05% 0% 6.9% 3.64% 5.07% 4.72%
Book Value Per Share 1 11.91 27.69 23.93 25.06 26.09 28.89 33.14 38.54
Change - 132.51% -13.6% 4.74% 4.13% 10.72% 14.72% 16.28%
EPS 1 2.44 0.08 2.11 3.81 4.5 6.384 7.694 8.775
Change - -96.72% 2,537.5% 80.57% 18.11% 41.86% 20.52% 14.05%
Nbr of stocks (in thousands) 1,312,660 1,549,159 1,549,528 1,549,926 1,550,317 1,550,658 1,550,658 1,550,658
Announcement Date 11/02/21 10/02/22 09/02/23 08/02/24 06/02/25 - - -
1USD
Estimates
2025 *2026 *
P/E ratio 21.9x 18.2x
PBR 4.84x 4.22x
EV / Sales 4.1x 3.76x
Yield 2.3% 2.41%
More valuation ratios * Estimated data

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
139.98USD
Average target price
179.12USD
Spread / Average Target
+27.96%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Financials AstraZeneca PLC